Background: Sickle cell disease (SCD), a hereditary hemoglobinopathy, is associated with substantial maternal morbidity and mortality.Physiological changes of pregnancy often exacerbate complications in women with SCD, leading to poor maternal and fetal outcomes.This study evaluates the incidence and determinants of maternal deaths among pregnant women with SCD at a tertiary care center in Central India.Materials and methods: A cross-sectional observational study was undertaken at Government Medical College, Nagpur, from January 2022 to December 2024.All obstetric patients with confirmed SCD were included.Maternal outcomes (mortality, complications such as acute chest syndrome, preeclampsia, and vaso-occlusive crisis) and pregnancy outcomes (abortion, stillbirth, preterm delivery, mode of delivery, hemoglobin levels, and transfusion needs) were analyzed.Results: Out of 900 obstetric admissions with SCD, 27 maternal deaths were recorded in homozygous cases (HbSS), contributing 11.89% of all maternal deaths during the study period.Nearly three-fourths of the deaths (74.07%) occurred among unbooked referrals.The highest mortality was observed in women aged 26-30 years (48.14%), with 62.95% of deaths occurring postpartum.Vaso-occlusive crises and pulmonary embolism were the leading causes of death.Severe anemia at presentation was noted in 18.5% of cases.Conclusion: Maternal deaths in SCD remain high, particularly among unbooked and late-referred patients.Strengthening antenatal surveillance, timely diagnosis, multidisciplinary care, and postnatal follow-up are crucial to reducing preventable mortality in this high-risk group.
Chafale et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: